Amir Fathi, MD, discusses one of the biggest nonfinancial barriers to bispecific therapies: the expertise required to safely ...

A new study by Indiana University School of Medicine researchers has revealed a breakthrough in the fight against acute myeloid leukemia, one of the most aggressive and fatal blood cancers in adults.

The patients receiving AHSCT had 5-year LFS of 46.3% and OS of 53.3%, which were better outcomes than those of the MRC UKALL XII/ECOG E2993 trial conducted from 2006 to 2010.

Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth and persistence of leukemia cells—and developed a novel immunotherapy that can disrupt that loop to ...

Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progresses rapidly, making immediate treatment essential. While chemotherapy and targeted drugs have ...

Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive, molecularly distinct leukemia subtype marked by menin-dependent transcriptional dysregulation, poor response ...

Multiple steps are involved in chronic lymphocytic leukemia (CLL) pathophysiology, and various factors are related to the development the disease: cytogenetic aberrations, antigenic triggers activated ...

Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL). ALL is a rare, rapidly progressing cancer of the blood and bone marrow ...

The review sheds light on the role of post-transcriptional RNA modifications in normal hematopoietic development and acute myeloid leukemia, and highlights novel therapeutic targets and treatment ...

For example, in acute promyelocytic leukemia (APL) a translocation t (15;17) produces a PML-RARα fusion protein.

Acute undifferentiated leukemia is a very rare type of blood cancer that doesn’t have any of the markers typically used to classify leukemias as lymphocytic or myeloid.